Coya Completes Enrollment Phase 2/3 ALS Trial
Coya Therapeutics finished enrolling its Phase 2/3 ALSTARS trial and announced plans for an open-label extension. The company reported $35.8 million in cash as of September 30, 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed